You can buy or sell Novartis and other stocks, options, ETFs, and crypto commission-free!
Novartis AG, also called Novartis, is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. Read More The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Basel, Basel-Stadt (Basle Town)
52 Week High
52 Week Low
For Anderson family, an early bet on SMA gene therapy
NEW YORK, May 24 (Reuters) - When Malachi Anderson was diagnosed with a rare and often deadly disease called spinal muscular atrophy (SMA) as an infant nearly four years ago, his parents Tina and Torence had a decision to make.
Wall Street Journal12m
At $2 Million, New Novartis Drug Is Priciest Ever
The world’s most expensive medicine is about to hit the market. A one-time treatment for a devastating infant muscle-wasting disease won approval from the U.S. Food and Drug Administration Friday. Its maker Novartis AG NVS 3.65% says the gene therapy will cost $2.125 million. The therapy, called Zolgensma, treats an inherited disease called spinal muscular atrophy, or SMA, whose victims typically die before the age of two if untreated. It is the latest gene therapy—a technique that introduces new DNA into...
FDA OKs Novartis' alpelisib for certain type of breast cancer; shares up 4%
The FDA approves Novartis' (NVS +3.7% ) Piqray (alpelisib), a PI3K inhibitor, for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative PIK3CA-mutated advanced or metastatic breast cancer in patients who have progressed after receiving endocrine-based therapy.
Expected Jul 18, Pre-Market